Back

BioMarin appoints Bristol Myers Squibb research chief Robert Plenge to board

Verifying
  • BioMarin appointed Robert Plenge, M.D., Ph.D., to its Board of Directors.
  • September 10, 2026 marked the effective date of Plenge’s appointment.
  • BioMarin has nine commercial therapies and six approved first-in-disease medicines.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.